中新网9月20日电 国家发展和改革委员会今日在其官方网站公布《关于进一步加强药品安全信用体系建设工作的指导意见》。意见要求，要加快完善药品安全领域信用制度建设，抓紧研究制定药品安全领域信用制度规范。

Beijing September 20, the national development and reform commission today in its official website[On further strengthening drug safety credit system construction work instruction opinion].Opinion request,To speed up the perfect drug safety credit system construction field,To study and establish drug safety credit system specification field.

　　意见强调，抓紧研究制定药品安全领域信用制度规范，要通过药品安全信用征集制度、信用评价制度、信用披露制度、信用分类监管制度的制定和实施，建立药品企业信用档案，做到真实、准确、可追溯，并规定诚信记录的标识、存放、保护、检索、留存和处置等行业规范。

Opinion emphasize,To study and establish drug safety credit system specification field,The drug safety credit solicitation system/Credit evaluation system/Credit disclosure system/Credit classified supervision system of formulation and implementation,Establish the enterprise credit files,Do real/accurate/The traceability,And provisions of the credit record identification/storage/protection/retrieval/Retention and disposal of the industry standard.

　　意见要求，根据药品安全信用评价结果的差别确定不同的监管力度，充分发挥药品安全信用差异对药品企业的奖惩功能，切实提高药品安全信用监管水平，保障人民群众用药安全有效。

Opinion request,According to the drug safety credit evaluation result differences determine different supervision dynamics,Give full play to the drug safety credit differences on pharmaceutical enterprise the rewards and punishment function,In order to improve drug safety credit supervision level,Protecting the people's drug is safe and effective.